欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 05-12 16:08:03

7.100

+0.090

+1.28%

最高7.100	最低6.920	成交量61.90万
今开7.030	昨收7.010	日振幅2.57%
总市值57.87亿	流通市值57.87亿	总股本8.15亿
成交额432.41万	换手率0.08%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.1,"timestamp":1778573283004,"preClose":7.01,"halted":0,"volume":619000,"delay":0,"changeRate":0.012838801711840209,"floatShares":815000000,"shares":815000000,"eps":-0.2,"marketStatus":"未开盘","change":0.09,"latestTime":"05-12 16:08:03","open":7.03,"high":7.1,"low":6.92,"amount":4324095,"amplitude":0.025678,"askPrice":7.1,"askSize":4500,"bidPrice":6.95,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":-0.222562,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":7.01,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"volumeRatio":0.907769,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/wiki","defaultTab":"wiki","newsList":[{"id":"2634107952","title":"152亿美元！恒瑞为何能让全球制药巨头疯狂？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634107952","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634107952?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:11","pubTimestamp":1778595060,"startTime":"0","endTime":"0","summary":"5月12日午盘，恒瑞医药突然放出一枚深水炸弹：和全球制药巨头百时美施贵宝（BMS）达成了重磅合作！这笔买卖到底有多大？潜在总交易额高达152亿美元！BMS先支付9.5亿美元首付和近期付款，后面只要药物研发能顺利推下去，恒瑞还能拿到上百亿的里程碑付款，甚至未来的销售分成！这次合作涉及13款早期创新药，主攻肿瘤、血液和免疫疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734849437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734849437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212162","title":"欧康维视生物-B(01477)授出购股权及奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634212162?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:26","pubTimestamp":1778592417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，董事会认为有必要实施激励措施以支持本集团的战略增长目标，并维持人才招聘及留任方面的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021349","title":"GIC Private Limited增持歌礼制药-B(01672)12.2万股 每股作价16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634021349?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1191","BK1161","GIC","BK4104","BK1574","EWH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290057","title":"剂泰科技港股上市在即：AI制药三小龙会师港股 贝莱德领衔基石 2025年收入增长靠首付款 长期仍具不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290057","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634290057?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:46","pubTimestamp":1778582760,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！本次基石投资者合计认购占比约54.9%。2025年公司实现收入1.05亿元，主要来自管线产品MTS-004的授权首付款，未来商业化收入规模与节奏均存在较大不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-05-12/doc-inhxrwqf8212666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BGHQF748.EUR","LU0208291251.USD","LU0320765489.SGD","01477","LU2430703178.SGD","LU0157215616.USD","ARTY","LU1670628061.USD","LU1201861249.SGD","IE00BVYPNW00.USD","IE00B3PB1722.GBP","IE00B64PRP62.GBP","LU2264538146.SGD","LU1074936037.SGD","LU2430703095.HKD","BK4535","IE00BVYPNV92.GBP","BK4581","LU1291159041.SGD","LU0640476718.USD","LU0731783394.SGD","BLK","VXUS","BK1191","LU0731783048.USD","AIPO","LU0130102774.USD","LU1509826696.USD","LU0742537680.HKD","BK4135","BK4588","LU0772969993.USD","LU1064131342.USD","IE00B3QW5Z07.USD","LU1988902786.USD","IE00B42XCP33.USD","LU1280957306.USD","AGIX","LU1366333091.USD","IPOS","LU1599440770.SGD","LU1989771016.USD","LU2592432038.USD","BK4533","LU2430703251.USD","LU1481011911.USD","LU1481011671.HKD","CHAT","BK4567","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634886402","title":"白云山(00874)：天心制药获得注射用头孢呋辛钠0.5g坎地沙坦酯片4mg《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2634886402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634886402?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:33","pubTimestamp":1778492035,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，近日，公司子公司广州白云山天心制药股份有限公司(以下简称“天心制药”)收到国家药品监督管理局签发的注射用头孢呋辛钠0.5g(按C16H16N4O8S计)、坎地沙坦酯片4mg《药品补充申请批准通知书》。天心制药本次获得注射用头孢呋辛钠0.5g(按C16H16N4O8S计)、坎地沙坦酯片4mg《药品补充申请批准通知书》,表明上述药品的杂质药学研究获认可，有利于提升上述产品的质量控制能力和市场竞争力。本次获得上述《药品补充申请批准通知书》，对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","01477","BK0239","BK0096","BK0183","BK1197","BK0196","BK1191","BK0188","BK0028","BK0097","BK0175","BK1574","BK0070","00874","600332","BK1521","BK1515","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408851","title":"港股异动 | 来凯医药-B(02105)午后涨超10% 齐鲁制药推进LAE002上市申请 公司有望获首付款及里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408851","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408851?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:32","pubTimestamp":1778481147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后涨超10%，截至发稿，涨9.63%，报14.8港元，成交额6089.13万港元。4月30日，齐鲁制药官方宣布，由其独家引进中国区域研发与商业化权益的创新靶向药afuresertib临床研究达到主要终点，齐鲁制药独家引进推进国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191","BK1161","02105","VXUS","BK4588","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633488227","title":"优德精密：制药模具及医疗器材零部件营业收入为7,150,579.74元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633488227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633488227?lang=zh_cn&edition=full","pubTime":"2026-05-08 11:35","pubTimestamp":1778211314,"startTime":"0","endTime":"0","summary":"证券之星消息，优德精密(300549)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司医疗行业销售4000多万主要是哪些产品？优德精密回复：尊敬的投资者，您好！公司2025年度年报披露的制药模具及医疗器材零部件营业收入为7,150,579.74元，占营业收入比重为2.26%，相关产品请详见2025年年报第三节管理层讨论与分析中“一、报告期内公司从事的主要业务”之“2.公司的主要产品及用途”。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800017251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159797","01477","300549"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633114281","title":"安杰利尼制药41亿美元收购Catalyst Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2633114281","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633114281?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:47","pubTimestamp":1778147220,"startTime":"0","endTime":"0","summary":"两家公司周四官宣，罕见病药企 Catalyst Pharmaceuticals 将被医疗集团 Angelini Pharma 以41 亿美元收购。　　安杰利尼每股出价 31.50 美元，对应总对价约 35 亿欧元、折合 41 亿美元；收购价较该股 4 月 22 日收盘价溢价 21%。　　Catalyst 总裁兼 CEO 表示，这笔交易为股东带来确定性现金收益 + 可观溢价。　　安杰利尼计划把 Catalyst 的药品管线与商业化渠道，和自身脑健康领域专业能力及产品整合，搭建下一代罕见病治疗平台。　　此次收购也标志着安杰利尼正式进军美国市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-07/doc-inhxahrf2847544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633112391","title":"剂泰科技即将结束招股 创AI制药基石规模新高 | 港股打新","url":"https://stock-news.laohu8.com/highlight/detail?id=2633112391","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633112391?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:34","pubTimestamp":1778146440,"startTime":"0","endTime":"0","summary":"5月7日，英派药业-B、剂泰科技-P持续招股，均拟于5月13日港股上市，其中剂泰科技-P有望成为“全球AI纳米递送第一股”。英派药业-B公司行业：生物科技公司简介：公司成立于2009年，是一家处于商业化阶段的生物技术公司，致力于在全球范围内推进基于合成致死机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073730207925.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073730207925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159381","BK4588","BK4585","BK1574","IPOS","BK1191","VXUS","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633190028","title":"港股异动 | 来凯医药-B(02105)尾盘涨超5% 齐鲁制药将推进LAE002国内上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633190028","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633190028?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:23","pubTimestamp":1778138614,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B尾盘涨超5%，截至发稿，涨3.83%，报13.82港元，成交额2591万港元。公开资料显示，LAE002是来凯医药自主开发的一种AKT强效抑制剂。根据来凯医药与齐鲁制药所签协议，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。此外，来凯医药有权基于中国地区该药物的未来净销售额收取销售分成，分成比率在十余个至二十余个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IPOS","BK1574","BK1161","01477","BK4585","VXUS","02105","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633192242","title":"国金证券：制药供应链景气度上行信号明确 内外需共振带动业绩提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2633192242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633192242?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:26","pubTimestamp":1778135178,"startTime":"0","endTime":"0","summary":"国金证券主要观点如下：CXO产业链：景气度上行信号明确，全球生物医药投融资水平显著改善，行业复苏动能持续增强2025年全年，境外生物医药投融资额达1981亿美元，较2024年的1261亿美元大幅提升57%;国内市场在持续的BD催化下，药企合作意愿提升，需求端呈现爆发式增长。该行认为，2026年CXO板块景气度上行趋势明确，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600109","BK0012","BK0201","BK0276","BK0183","BK1574","BK0028","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126353731","title":"欧康维视生物-B更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126353731","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126353731?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:32","pubTimestamp":1778070737,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2026年5月6日披露截至2026年4月30日的股份变动月报表。报告期内，公司法定股本维持5,000,000,000股，面值每股0.00001美元，合计50,000美元，较上月未发生变化。截至4月30日，已发行普通股815,382,414股，库藏股20,949,500股，合计836,331,914股，与上月末持平。公司确认已按照香港联交所《上市规则》及相关法律法规履行本月所有发行及库藏股变动事项的审批和披露要求。截至本报告期末，公司整体股本结构保持稳定。本公告由公司董事Lian Yong CHEN签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633997732","title":"国金证券：制药行业赛道分化 创新药板块高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2633997732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633997732?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:50","pubTimestamp":1778035836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，多重利好叠加下，创新药板块进入业绩、估值、事件三重周期叠加的黄金布局期，建议重点关注龙头标的、Biotech扭亏标的，以及ASCO等学术会议催化标的，把握创新药中长期成长机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK0276","BK1191","BK0201","06978","BK1574","600109","159992","BK1161","BK0183","BK0028","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633975038","title":"歌礼制药-B(01672)将携多个项目数据亮相第33届欧洲肥胖症大会(ECO 2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633975038","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633975038?lang=zh_cn&edition=full","pubTime":"2026-05-06 08:12","pubTimestamp":1778026375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，将在2026年5月12日至15日于土耳其伊斯坦布尔举行的第33届欧洲肥胖症大会上，以壁报形式展示多个项目。展示内容包括关于ASC47I期数据的壁报，其联合司美格鲁肽在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达111.8%;以及关于ASC36临床前数据的壁报，其在非人灵长类动物模型中的平均表观半衰期为32天，比petrelintide长6倍，在饮食诱导肥胖大鼠模型中减重效果较 petrelintide相对提升91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","01672","ECO","LU0997586861.USD","BK4144","BK1574","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699596","title":"1.48亿美元“买方天团”，剂泰科技（7666.HK）凭什么拿到这份顶配基石名单？","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699596","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633699596?lang=zh_cn&edition=full","pubTime":"2026-05-05 11:24","pubTimestamp":1777951461,"startTime":"0","endTime":"0","summary":"“AI制药三小龙”齐聚港交所，谁的呼声最高，以及如何看？","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/137.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/137.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4622941","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["01477","CHAT","BK1574","BK1191","BK4588","AGIX","AIYY","07666","BK4023","BK4585","VGT","BK4587","BK4528","BK4551","BK4543","ARTY","AIPO","AI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2632533869","title":"德勤研报：减肥药推动的增长正使制药行业面临风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2632533869","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632533869?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:14","pubTimestamp":1777896840,"startTime":"0","endTime":"0","summary":"德勤的一项最新研究显示，由于减肥药和糖尿病药物需求激增，盈利能力大幅攀升，制药行业正面临“泡沫效应”带来的风险。对Wegovy和Zepbound等药物的需求已将研发回报率推至多年来的最高水平，但德勤周一发布的报告指出，这实际上掩盖了行业其他领域所面临的压力。　　报告发现，16年来首次，减肥疗法超过肿瘤学，成为后期研发管线价值最大的贡献领域。德勤认为，这加大了企业对特定治疗领域冲击的暴露风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-04/doc-inhwtvtx3583689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632601714","title":"生物制药收购交易狂飙，第一季度霸主买家榜出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2632601714","media":"第一财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632601714?lang=zh_cn&edition=full","pubTime":"2026-05-03 16:32","pubTimestamp":1777797122,"startTime":"0","endTime":"0","summary":"今年以来，大型制药商收购狂潮势头较前几年更猛，全球生物制药行业并购交易有望在2026年迎来丰收年。研究机构Dealogic的数据显示，全球第一季度生物技术领域的并购交易总额已高达840亿美元，较一年前的444亿美元几乎实现翻番，这是自2019年全球并购交易创下历史新高以来表现最为强劲的第一季度。今年第一季度，礼来、吉利德科学、默沙东等公司在收购方面的花费排名居前。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605033727650388.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605033727650388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","01477","AGIX","CHAT","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632166670","title":"深度复盘国泰海通警示函事件：普利制药造假案背后的“看门人”失守与整合阵痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2632166670","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632166670?lang=zh_cn&edition=full","pubTime":"2026-05-03 00:02","pubTimestamp":1777737720,"startTime":"0","endTime":"0","summary":"　　随着注册制改革的纵深推进，监管层对中介机构“看门人”责任的追责力度正在触及灵魂。　　2026年3月20日，上海证监局一纸公告将这家新组建的券商巨头推至风口浪尖。国泰海通证券因在海通时代承接的普利制药保荐项目中存在严重执业不规范，被出具警示函。这不仅是一张简单的罚单，更是这家“航母级”券商在合并整合期面临的内控大考。　　此次风波的源头，指向了已因财务造假退市的海南普利制药股份有限公司。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-03/doc-inhwpucz1381405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191","BK1564","BK0028","BK1147","601211","BK0188","02611","BK0201","BK0276","BK0184","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631650806","title":"港股异动 | 歌礼制药-B(01672)早盘涨超3% 公司将携多个项目数据亮相ADA 2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2631650806","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631650806?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:34","pubTimestamp":1777520091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨超3%，截至发稿，涨2.06%，报16.85港元，成交额736.72万港元。消息面上，歌礼制药宣布，将在6月5日至8日于路易斯安那州新奥尔良举行的美国糖尿病协会2026年度科学会议上，以壁报形式展示多个项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK1161","VXUS","BK1515","01477","BK1574","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575201","title":"歌礼制药-B(01672)将携多个项目数据亮相美国糖尿病协会2026年度科学会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575201","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631575201?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:10","pubTimestamp":1777507846,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，将在2026年6月5日至8日于路易斯安那州新奥尔良举行的美国糖尿病协会(ADA)2026年度科学会议上，以壁报形式展示多个项目。展示内容包括ASC39(一款治疗肥胖症的类似eloralintide、具有选择性的强效口服小分子胰淀素受体激动剂)的临床前数据，其入选为最新突破(late breaking)壁报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1161","BK1515","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0247},{"period":"1month","weight":-0.1235},{"period":"3month","weight":0.0245},{"period":"6month","weight":-0.1895},{"period":"1year","weight":0.3654},{"period":"ytd","weight":-0.0405}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.0337},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.107474},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}